McKesson (NYSE:MCK) is set to post its quarterly earnings results after the market closes on Thursday, May 6th. Analysts expect McKesson to post earnings of $5.00 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
McKesson (NYSE:MCK) last released its quarterly earnings results on Monday, February 1st. The company reported $4.60 EPS for the quarter, topping the consensus estimate of $4.13 by $0.47. The company had revenue of $62.60 billion for the quarter, compared to analyst estimates of $61.70 billion. McKesson had a return on equity of 45.52% and a net margin of 0.95%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.81 earnings per share. On average, analysts expect McKesson to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.
NYSE:MCK opened at $192.12 on Tuesday. The firm has a market cap of $30.58 billion, a P/E ratio of 14.62, a PEG ratio of 1.70 and a beta of 0.94. The company has a current ratio of 0.99, a quick ratio of 0.56 and a debt-to-equity ratio of 0.96. The stock’s 50 day simple moving average is $191.70 and its 200-day simple moving average is $179.04. McKesson has a 12-month low of $125.65 and a 12-month high of $198.43.
McKesson declared that its board has initiated a share buyback plan on Tuesday, February 2nd that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 6.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.
A number of research analysts have recently issued reports on the company. Cowen boosted their target price on McKesson from $210.00 to $224.00 and gave the company an “outperform” rating in a report on Tuesday, March 2nd. Morgan Stanley boosted their target price on McKesson from $219.00 to $226.00 and gave the company an “overweight” rating in a report on Wednesday, February 3rd. Deutsche Bank Aktiengesellschaft upped their price objective on McKesson from $222.00 to $231.00 and gave the stock a “buy” rating in a report on Wednesday, February 3rd. Argus raised McKesson from a “hold” rating to a “buy” rating and set a $230.00 price objective on the stock in a report on Tuesday, March 30th. Finally, Credit Suisse Group upped their price objective on McKesson from $178.00 to $192.00 and gave the stock a “neutral” rating in a report on Wednesday, February 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $193.31.
In other news, CEO Brian S. Tyler sold 5,510 shares of the company’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $183.38, for a total value of $1,010,423.80. Following the sale, the chief executive officer now directly owns 24,500 shares in the company, valued at $4,492,810. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 5,511 shares of the company’s stock in a transaction on Thursday, April 15th. The shares were sold at an average price of $191.41, for a total value of $1,054,860.51. Following the completion of the sale, the chief executive officer now owns 24,501 shares in the company, valued at $4,689,736.41. The disclosure for this sale can be found here. 0.28% of the stock is owned by corporate insiders.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.
See Also: What is the price-sales ratio?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.